Gyre Therapeutics, Inc.
GYRE
Last
$7.04
Day
+4.1%
1y
-5.5%
5y
+0.4%
52w
-28.2%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0627d
EMA 21
7.05
EMA 50
6.89
EMA 200
7.10
20d high
-12.6%
5y high
-77.8%
5y range
5th
Positions held
Your positionsGYRE isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
10
Hold
watch
Signal
Neutral
Target
$7.39
Stop
$6.23
Stop distance
11.5%
Target vs last
+5.0%
Fundamentals
| Market cap | $716.79M | Enterprise value | $702.40M | Trailing P/E | — | Forward P/E | 112.67 |
| PEG | — | Price / book | 6.64 | Beta | 4.74 | Dividend yield | 0.00% |
| Revenue growth | -2.1% | Earnings growth | — | Gross margin | 93.8% | Operating margin | -47.6% |
| Profit margin | -19.3% | ROE | -17.4% | ROA | -5.4% | Debt / equity | 0.02 |
| Current ratio | 4.26 | Free cash flow | $1.88M | Analyst recommendation | none | Mean target | $18.67 |
| 52w high | $9.42 | 52w low | $5.44 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $29.1M | $22.5M | $37.2M | $30.6M | $29.7M | — |
| Op margin | -47.6% | -30.2% | 0.3% | 22.7% | -7.5% | — |
| Net income | -$10.6M | -$8.7M | -$1.7M | $3.6M | $0.6M | — |
| Gross margin | 92.4% | 94.6% | 95.3% | 94.7% | 96.1% | — |
| Gross profit | $26.9M | $21.3M | $35.5M | $28.9M | $28.6M | — |
| Operating income | -$13.9M | -$6.8M | $0.1M | $6.9M | -$2.2M | — |
- Revenue +29% vs prior quarter ($29M vs $23M).
- Gross margin 92.4% (was 94.6% prior quarter).
- Operating margin compressed to -47.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $117M | $106M | $113M | $102M | — |
| Op margin | 9.9% | 15.3% | 16.9% | 9.0% | — |
| Net income | $5.0M | $12.1M | -$92.9M | $2.3M | — |
| Gross margin | 95.4% | 96.3% | 95.9% | 95.3% | — |
| Gross profit | $111M | $102M | $109M | $97.5M | — |
| Operating income | $11.5M | $16.2M | $19.2M | $9.2M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-03 · Gyre Therapeutics to Participate in Upcoming September Investor Conferences
2026-08-07 · Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
2026-08-07 · Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
2026-07-16 · Gyre Therapeutics Appoints Three New Members to its Board of Directors
Price (daily)
Full chart · RSI · MACD · patternsGYRE · daily-9.7% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin